Cancer Supportive Care Drugs Market Size, Sector / Industry Report & Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Cancer Supportive Care Drugs Market


The global Cancer Supportive Care Drugs market size is projected to reach US$ 22.85 billion by 2026, from US$ 21.52 billion in 2020, at a CAGR of 1% during 2021-2026.Large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are anticipated to drive the growth.

According to estimates from the International Agency for Research on Cancer (IARC), 12.7 million people are diagnosed with cancer and 7.6 million deaths are recorded every year. Lung and breast cancer are the most prominent cancer types with the highest demand for supportive care drugs.

China and India are among promising destinations for cancer supportive care market expansion. Factors such as growing uptake of biosimilar, beneficial healthcare reforms, and low-cost base are providing a fillip to the market in these two countries.

Several unmet needs remain in the cancer supportive care segment. Current treatment approaches provide only symptomatic relief. Effective analgesic drugs with lower risk of tolerance and abuse remain a key area of unmet need in the cancer supportive drugs market.

Market Segmentation, Outlook & Viewpoint: Global Cancer Supportive Care Drugs Market

Therapeutic Class Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
G-CSFs (Granulocyte-colony Stimulating Factors)
  
ESAs (Erythropoiesis Stimulating Agents)
  
Anti-emetics
  
Bisphosphonates
  
Opioids
  
NSAIDs

Key Players, Recent Developments & Regional Insights: Global Cancer Supportive Care Drugs Market

The major drug classes involved in cancer supportive care include G-CSFs for treatment of neutropenia (CIN), ESAs for Anemia (CIA), antiemetics for nausea and vomiting (CINV), bisphosphonates for cancer induced bone diseases, and opioids and NSAIDs for treatment of cancer pain. Among these therapeutic classes, granulocyte stimulating factors (G-CSFs) such as Amgens Neupogen and Neulasta accounted for the largest share in 2018 followed by opioids. The report highlights brands prescribed in cancer supportive care such as Amgens Neupogen, Neulasta, Epogen and Xgeva, Mercks Emend, Roches NeoRecormon, Helsinns Aloxi, Herons Sustol, and Cinvanti among others.

The share for G-CSF drug class is expected to decline through the forecast period due to key patent losses and less use of myelosuppressive chemotherapy. Class of G-CSFs and ESAs have seen most number of biosimilar products, which has enabled increased access to affordable care for patients. Anti-emetics drug class is anticipated to post healthy growth during the same period, owing to new product launches. Targeted therapies currently dominate the space and are estimated to grow during the forecast period. Factors such as increasing use of immuno-oncology agents are poised to restrain the growth of the cancer supportive care drugs market over the coming years.

Pipeline Insights

Currently more than 10 products are undergoing clinical trials for treatment of various side-effects of cancer therapy. Some of the drugs are poised to aim at new molecular targets for treating side-effects in the cancer supportive care segment. Several key players are projected to work towards addressing unmet needs, identifying new targets, and consequentially develop stronger drug pipelines.

As per the findings of the report, leading pipeline drugs such as Tanezumab and Rolontis are likely to be launched during the forecast period. Results from clinical trials of these drugs reported positive primary and secondary endpoint data. These drugs utilize improved drug delivery technologies to optimize efficacy and lower adverse side-effects.

Regional Insights

North America led the market with more than 42.0% share in 2018. While the number of biosimilars launched in U.S. is low, biosimilar penetration is anticipated to increase owing to twice the average price of biologics.

Japan has witnessed significant uptake of biosimilars over the past few years. Rising incidence of cancer along with large number of side-effects associated with cancer treatment is one of the key factors anticipated to stimulate cancer supportive drugs market growth. Growing uptake of biosimilars, expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are also benefiting the cancer supportive care market in Japan.

Cancer Supportive Care Drugs Market Share Insights

Some of the players operating in this market are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro. Approval of Sustol and Cinvanti are expected to create significant market opportunity for Heron Pharma during the forecast period. The company also has a Phase III product candidate indicated for cancer pain.

Patent expirations and rising biosimilar competition have impacted several companies, most notably Amgen and Roche. Sandoz, Hospira, Teva Pharmaceuticals, 3SBio, and BioSidus are some of the major players.

Key Insights Covered: Global Cancer Supportive Care Drugs Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Cancer Supportive Care Drugs industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Cancer Supportive Care Drugs industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Cancer Supportive Care Drugs industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Cancer Supportive Care Drugs industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Cancer Supportive Care Drugs industry.

Research Methodology: Global Cancer Supportive Care Drugs Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other